Chemocentryx Stock Financials

CCXI -  USA Stock  

USD 25.26  1.12  4.64%

Understanding current and past Chemocentryx Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Chemocentryx's financial statements are interrelated, with each one affecting the others. For example, an increase in Chemocentryx's assets may result in an increase in income on the income statement. Because of this, it is necessary to analyze all of Chemocentryx's financials over time to get the whole picture.
Chemocentryx Enterprise Value is most likely to increase significantly in the upcoming years. The preceding year's Enterprise Value was reported at 4.93 Billion. The current Invested Capital is estimated to increase to about 618.1 M, while Net Income Per Employee is projected to decrease to (515 K).
Use fundamental data analysis to double-check all available reported financial drivers of Chemocentryx to find out if markets are presently mispricing the company. We have analyzed and interpolated thirty-four available fundamental indicators for Chemocentryx, which can be compared to its rivals. To make sure the equity is not overpriced, please confirm all Chemocentryx financials, including its cash per share, market capitalization, and the relationship between the revenue and cash flow from operations . Given that Chemocentryx has a price to earning of 40.53 X, we suggest you to validate Chemocentryx prevailing market performance to make sure the company can sustain itself down the road. Use Chemocentryx to enhance returns of your portfolios. The stock experiences a very speculative upward sentiment. Check odds of Chemocentryx to be traded at $31.58 in 90 days.

Chemocentryx Fundamentals 

With this module, you can analyze Chemocentryx financials for your investing period. You should be able to track the changes in Chemocentryx individual financial statements over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.
The fundamental analysis of Chemocentryx is a critical element in measuring its lifeblood. The essential information of the day-to-day investment outlook for Chemocentryx includes many different criteria found on its balance sheet. For example, investors should never minimize Chemocentryx's ability to pay suppliers or employees on time, making sure interest payments are not accumulating or correctly timing where and how to re-invest extra cash. Any individual investor needs to monitor Chemocentryx's cash flow, debt, and profitability to effectively and accurately make more informed decisions on whether to invest in Chemocentryx.

Chemocentryx Cash

Chance Of Financial Distress
Less than 18
Chemocentryx has less than 18 (%) percent chance of experiencing financial distress in the next two years of operations. The calculation of odds of distress for Chemocentryx stock is tightly coupled with the Probability of Bankruptcy. It complements the equity performance score by supplying investors with insight into company financials without requiring them to know too much about all of the complex accounting and financial indicators surrounding the entity. More Info
The data published in Chemocentryx's official financial statements usually reflect Chemocentryx's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Chemocentryx. For example, before you start analyzing numbers published by Chemocentryx accountants, it's critical to develop an understanding of what Chemocentryx's liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of Chemocentryx's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Chemocentryx's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Chemocentryx's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Chemocentryx. Please utilize our Beneish M Score to check the likelihood of Chemocentryx's management to manipulate its earnings.

Chemocentryx Company Summary

Chemocentryx competes with Brickell Biotech. ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It develops Avacopan, an orally administered selective complement 5a receptor inhibitor for the treatment of anti-neutrophil cytoplasmic autoantibody-associated vasculitis and completed Phase II clinical trial for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy. The company is also developing CCX559, an orally-administered inhibitor for programmed death protein 1programmed death-ligand 1 for the treatment of various cancers and CCX507, an orally-administered inhibitor of the chemokine receptor CC9, which has completed Phase I clinical trial or the treatment of inflammatory bowel disease. In addition, it develops CCX587 for the treatment of TH17 driven diseases. ChemoCentryx, Inc. was incorporated in 1996 and is headquartered in San Carlos, California.
Healthcare, Biotechnology
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
CIK Number0001340652
RegionNorth America
LocationCalifornia; U.S.A
Business Address835 Industrial Road,
Phone650 210 2910
CurrencyUSD - US Dollar
You should never invest in Chemocentryx without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Chemocentryx Stock, because this is throwing your money away. Analyzing the key information contained in Chemocentryx's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.

Chemocentryx Key Financial Ratios

Generally speaking, Chemocentryx's financial ratios allow both analysts and investors to convert raw data from Chemocentryx's financial statements into concise, actionable information that can be used to evaluate the performance of Chemocentryx over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Chemocentryx reports annually and quarterly.

Chemocentryx Key Balance Sheet Accounts

201720182019202020212022 (projected)
Receivables51.09 M2.06 M176 K137 K157.55 K161.7 K
Accounts Payable1.4 M966 K1.53 M12.88 M11.59 M12.5 M
Total Assets189.33 M183.31 M209.08 M518.9 M596.73 M643.84 M
Current Assets179.83 M181.38 M174.36 M441.57 M507.81 M547.9 M
Assets Non Current9.5 M1.93 M34.72 M77.33 M88.93 M95.95 M
Cash and Equivalents40.02 M28.09 M39.18 M32.3 M37.14 M33.41 M
Deferred Revenue95.16 M134.56 M100.84 M36.59 M42.08 M61.48 M
Shareholders Equity79.27 M14.74 M66 M385.61 M443.45 M478.46 M
Investments95.2 M148.9 M163.06 M428.07 M492.28 M531.15 M
Investments Current87.27 M148.9 M133.61 M404.27 M464.91 M501.62 M
Total Liabilities110.06 M168.57 M143.08 M133.29 M153.28 M122.34 M
Current Liabilities32.94 M64.4 M59.08 M51.56 M59.29 M47.85 M

Chemocentryx Key Income Statement Accounts

An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket. The other reason investors look at the income statement is to determine what Chemocentryx's earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
201720182019202020212022 (projected)
Consolidated Income17.86 M(37.97 M)(55.49 M)(55.36 M)(49.82 M)(53.75 M)
Gross Profit82.5 M42.88 M36.13 M64.89 M74.62 M59.65 M
Net Income17.86 M(37.97 M)(55.49 M)(55.36 M)(49.82 M)(53.75 M)
Operating Expenses66 M83.14 M94.43 M120.07 M138.08 M109.59 M
Operating Income16.49 M(40.27 M)(58.3 M)(55.18 M)(49.66 M)(53.58 M)
Revenues82.5 M42.88 M36.13 M64.89 M74.62 M59.65 M

Chemocentryx Key Cash Accounts

Cash flow analysis captures how much money flows into and out of Chemocentryx. It measures of how well Chemocentryx is doing because it can show the actual money that comes into and out of the company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Chemocentryx brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money Chemocentryx had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Chemocentryx has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
201720182019202020212022 (projected)
Capital Expenditure(723 K)(838 K)(790 K)(15.41 M)(13.87 M)(14.23 M)
Depreciation Amortization and Accretion418 K512 K1.64 M2.77 M3.18 M3.43 M
Net Cash Flow or Change in Cash and Cash Equivalents28 M(11.93 M)12.17 M(6.88 M)(6.19 M)(6.36 M)
Issuance Purchase of Equity Shares3.27 M10.47 M96.13 M355.97 M409.37 M441.69 M
Net Cash Flow from Financing7.52 M24.7 M94.82 M356.62 M410.11 M442.49 M
Net Cash Flow from Investing15.6 M(53.07 M)(12.53 M)(282.36 M)(254.12 M)(260.81 M)
Net Cash Flow Investment Acquisitions and Disposals16.32 M(52.23 M)(11.74 M)(266.95 M)(240.26 M)(246.58 M)
Net Cash Flow from Operations4.88 M16.44 M(70.12 M)(81.14 M)(73.03 M)(74.95 M)
Share Based Compensation8.75 M10.83 M11.64 M22.91 M26.35 M28.43 M

Chemocentryx Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Chemocentryx's current stock value. Our valuation model uses many indicators to compare Chemocentryx value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Chemocentryx competition to find correlations between indicators driving Chemocentryx's intrinsic value. More Info.
Chemocentryx is rated second in earnings per share category among related companies. It is number one stock in cash per share category among related companies . The current Free Cash Flow is estimated to decrease to about (89.2 M). Comparative valuation analysis is a catch-all model that can be used if you cannot value Chemocentryx by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Chemocentryx's Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Chemocentryx's earnings, one of the primary drivers of an investment's value.

Chemocentryx Systematic Risk

Chemocentryx's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Chemocentryx volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was fourty-eight with a total number of output elements of thirteen. The Beta measures systematic risk based on how returns on Chemocentryx correlated with the market. If Beta is less than 0 Chemocentryx generally moves in the opposite direction as compared to the market. If Chemocentryx Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Chemocentryx is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Chemocentryx is generally in the same direction as the market. If Beta > 1 Chemocentryx moves generally in the same direction as, but more than the movement of the benchmark. View also all equity analysis or get more info about beta statistic functions indicator.

About Chemocentryx Financials

What exactly are Chemocentryx Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include Chemocentryx's income statement, its balance sheet, and the statement of cash flows. Potential Chemocentryx investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Chemocentryx investors may use each financial statement separately, they are all related. The changes in Chemocentryx's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Chemocentryx's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.
 2019 2020 2021 2022 (projected)
Accounts Payable1.53 M12.88 M11.59 M12.5 M
Receivables176 K137 K157.55 K161.7 K
There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines that you should keep in mind when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase year after year due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt to equity ratio because this number will tell you how much risk it has. If a company such as Chemocentryx is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to try and figure out if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that net revenue of Chemocentryx grown by more than 25% over the last five years, then there is a good chance that it will continue growing at least by 20% or more each year. On the other hand, if you see that net revenue has only grown by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it.

Chemocentryx Thematic Clasifications

Chemocentryx is part of Cancer Fighters investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Public companies from health care and pharmaceutical sectors that are focused on fighting cancer. Biotech and medical diagnostic companies that work on researching drugs or manufacturing of medical and therapeutics equipment that is directly related to the research, treatment, and detection of cancer or cancer related diseases
Cancer Fighters Idea
Cancer FightersView
This theme covers Public companies from health care and pharmaceutical sectors that are focused on fighting cancer. Biotech and medical diagnostic companies that work on researching drugs or manufacturing of medical and therapeutics equipment that is directly related to the research, treatment, and detection of cancer or cancer related diseases. Get More Thematic Ideas

Chemocentryx January 28, 2022 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Chemocentryx help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Chemocentryx. We use our internally-developed statistical techniques to arrive at the intrinsic value of Chemocentryx based on widely used predictive technical indicators. In general, we focus on analyzing Chemocentryx Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Chemocentryx's daily price indicators and compare them against related drivers.
Information Ratio(0.12)
Maximum Drawdown15.04
Value At Risk(6.44)
Potential Upside5.16
Continue to Trending Equities. Note that the Chemocentryx information on this page should be used as a complementary analysis to other Chemocentryx's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Money Managers module to screen money managers from public funds and ETFs managed around the world.

Complementary Tools for Chemocentryx Stock analysis

When running Chemocentryx price analysis, check to measure Chemocentryx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Chemocentryx is operating at the current time. Most of Chemocentryx's value examination focuses on studying past and present price action to predict the probability of Chemocentryx's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Chemocentryx's price. Additionally, you may evaluate how the addition of Chemocentryx to your portfolios can decrease your overall portfolio volatility.
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Is Chemocentryx's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Chemocentryx. If investors know Chemocentryx will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Chemocentryx listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Chemocentryx is measured differently than its book value, which is the value of Chemocentryx that is recorded on the company's balance sheet. Investors also form their own opinion of Chemocentryx's value that differs from its market value or its book value, called intrinsic value, which is Chemocentryx's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Chemocentryx's market value can be influenced by many factors that don't directly affect Chemocentryx's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Chemocentryx's value and its price as these two are different measures arrived at by different means. Investors typically determine Chemocentryx value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Chemocentryx's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.